Skip to main content
Fig. 1 | Arthritis Research & Therapy

Fig. 1

From: High level of serum complement 3 is a risk factor for vascular stenosis progression in TA patients receiving tocilizumab: a prospective observational study

Fig. 1

The treatment effect of tocilizumab. A The NIH scores of enrolled patients at baseline and after 6 months of treatment. B The dose of prednisone in enrolled patients at baseline and positive treatment effect of tocilizumab. C representative image of VSP in TA. D The incidence of VSP and VISE during follow-up. ****p < 0.0001. TA, Takayasu arteritis; VSP, vascular stenosis progression; VISE, vascular ischemic symptoms and events

Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us